High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma

Bone Marrow Transplantation
P C HuijgensG J Ossenkoppele

Abstract

In 90 consecutive patients with multiple myeloma, we investigated the feasibility of administering a tandem high-dose therapy regimen, using whole blood for rescue after the first and leucapheresis harvested between the two high doses, for rescue after the second high dose. After 5 days of G-CSF 1 litre of whole blood (WB) was obtained, left undisturbed at 4 degrees C and reinfused 24 h after HDM (140 mg/m(2)). Patients not in progression after 3-6 months were again mobilised, leucapheresed and treated with busulphan 16 mg/kg and cyclophosphamide 120 mg/kg (Bu/Cy) and reinfusion. In 90 patients, WB contained a mean (range) of 0.57 (0.02-3.22) x 10(6)/kg CD34(+) cells. Recovery after HDM was in 13 days for granulocytes and in 18 days for platelets, with 11 patients not recovering within 3 months. There were three toxic deaths. Sixty-six patients qualified for harvesting after HDM. In the first 11, marrow was harvested. The subsequent 55 patients were mobilised and in 45 the preset minimum of 1.5 x 10(6) CD34(+) cells was obtained. Forty-nine patients actually received Bu/Cy. Recovery after Bu/Cy and marrow reinfusion was in 35 days for granulocytes and 20 days for platelets, with two of five patients not recovering after 3 month...Continue Reading

References

Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W M GregoryJ S Malpas
May 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A C Buzaid, B G Durie
Jan 1, 1989·European Journal of Haematology. Supplementum·D E Bergsagel
Jul 1, 1986·Annals of Internal Medicine·R AlexanianD Dixon
May 24, 1984·The New England Journal of Medicine·B BarlogieR Alexanian
Apr 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D CunninghamJ Malpas
Nov 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G J OssenkoppeleP C Huijgens
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D H VesoleB Barlogie

❮ Previous
Next ❯

Citations

May 2, 2002·Anti-cancer Drugs·S Zweegman, P C Huijgens
Oct 1, 2004·Expert Review of Pharmacoeconomics & Outcomes Research·Martijn T GrootCarin A Uyl-de Groot
Dec 25, 2015·Expert Opinion on Biological Therapy·Massimo MartinoFortunato Morabito
Jan 19, 2005·European Journal of Haematology·C A Uyl-de GrootP C Huijgens
Nov 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Josien C RegelinkSonja Zweegman
Jan 10, 2002·Bone Marrow Transplantation·D H VesoleH M Lazarus
Sep 24, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Katharina KriegsmannPatrick Wuchter
May 20, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Felix KrummradtKatharina Kriegsmann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.